You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

2-hydroxyglutarate

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Glioma, Gliomas, High Grade Glioma Trial run by the National Cancer Institute (NCI) (3T MRI scanner)

Recruiting
  • Glioma
  • +4 more
  • 3T MRI scanner
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Non Invasive IDentification of Gliomas With IDH1 Mutation

Completed
  • Non Invasive Diagnosis of Glioma
    • Paris, Sélectionner..., France
      GH Pitié-Salpêtrière, 47 Bd de l'Hopital,
    Aug 25, 2021

    Clinical Development of MR Spectroscopy and Imaging in Brain

    Completed
    • Malignant Gliomas
    • +2 more
    • 3 Tesla Scanning
    • 7 Tesla Scanning
    • Dallas, Texas
      UT Southwestern Medical Center
    Jan 19, 2022

    Glioma, Brain Tumor, Primary Brain Tumor Trial in Miami (3T MRI Scanner)

    Recruiting
    • Glioma
    • +4 more
    • 3T MRI Scanner
    • Miami, Florida
      University of Miami
    Mar 15, 2022

    Glioma Trial in Paris (MRI)

    Not yet recruiting
    • Glioma
    • MRI
    • Paris, France
      Pitié-Salpetrière Hospital
    Jan 27, 2023

    Clinical Development of Cancer-Specific MRS Biomarkers in

    Completed
    • Malignant Gliomas
    • +2 more
    • 3 Tesla scanning
    • Dallas, Texas
      UT Southwestern Medical Center
    Jan 19, 2022

    Glioma Trial in Melbourne (Biopsy, Part A: AB-218, Surgery (maximal resection))

    Recruiting
    • Glioma
    • Biopsy
    • +3 more
    • Melbourne, Victoria, Australia
      Royal Melbourne Hospital
    Oct 11, 2022

    Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma Trial in Worldwide (AG-120, Placebo)

    Completed
    Has Results
    • Advanced Cholangiocarcinoma
    • Metastatic Cholangiocarcinoma
    • Scottsdale, Arizona
    • +48 more
    Dec 20, 2022

    Low-grade Glioma, IDH2 Gene Mutation, Recurrent Glioma Trial in Boston (Niraparib, Resection/Treatment with Niraparib)

    Recruiting
    • Low-grade Glioma
    • +4 more
    • Boston, Massachusetts
      Massachusetts General Hospital
    Oct 19, 2022

    Recurrent IDH1/2 Mutated Glioma Trial in Paris (Azacitidine)

    Recruiting
    • Recurrent IDH1/2 Mutated Glioma
    • Paris, France
      Pitie Salpetriere Hospital
    Aug 29, 2022

    Glioma, Malignant, Computer-Assisted Trial in Shanghai (Validation of IDH1 mutations from the radiomics model)

    Active, not recruiting
    • Glioma, Malignant
    • Computer-Assisted
    • Validation of IDH1 mutations from the radiomics model
    • Shanghai, Shanghai, China
      Huashan Hospital, Fudan University
    Jul 23, 2023

    Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic Trial (Ivosidenib)

    Not yet recruiting
    • Cholangiocarcinoma Non-resectable
    • Cholangiocarcinoma Metastatic
    • (no location specified)
    Oct 10, 2023

    Melanoma (Skin) Trial in Salt Lake City (Aspirin 81 mg, Aspirin 325mg, Placebo oral tablet)

    Completed
    • Melanoma (Skin)
    • Aspirin 81 mg
    • +2 more
    • Salt Lake City, Utah
      Huntsman Cancer Institute/University of Utah
    Feb 16, 2022

    Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1

    Not yet recruiting
    • Locally Advanced or Metastatic Conventional Chondrosarcoma With an IDH1 Mutation, Untreated or Previously Treated With 1 Systemic Treatment Regimen
    • Ivosidenib 500mg
    • Placebo
    • (no location specified)
    Nov 7, 2023

    IDH1-mutant Cholangiocarcinoma Trial (Ivosidenib, Recommended Combination Dose (RCD) of ivosidenib, Nivolumab)

    Not yet recruiting
    • IDH1-mutant Cholangiocarcinoma
    • (no location specified)
    Jun 29, 2023

    Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia

    Recruiting
    • Acute Myeloid Leukemia
    • +6 more
    • Biospecimen Collection
    • +2 more
    • Orange, California
    • +9 more
    Jan 27, 2023

    Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia Trial in Baltimore, Boston, Columbus (Enasidenib)

    Active, not recruiting
    • Acute Myeloid Leukemia
    • Chronic Myelomonocytic Leukemia
    • Baltimore, Maryland
    • +3 more
    Aug 8, 2022

    Brain Tumor Adult Trial in Salt Lake City (MR Perfusion Scan, 2HG Spectroscopy Scan)

    Active, not recruiting
    • Brain Tumor Adult
    • MR Perfusion Scan
    • 2HG Spectroscopy Scan
    • Salt Lake City, Utah
      Huntsman Cancer Institute
    Nov 21, 2022

    WHO Grade II Glioma Trial in Japan (DS-1001b)

    Active, not recruiting
    • WHO Grade II Glioma
    • Nagoya, Aichi, Japan
    • +10 more
    Feb 3, 2022

    Adult Gliomas, Mixed Trial in San Francisco (Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG), Magnetic Resonance Image

    Recruiting
    • Adult Gliomas, Mixed
    • Hyperpolarized Carbon 13 Alpha-ketoglutarate (HP C13-aKG)
    • Magnetic Resonance Image (MRI)
    • San Francisco, California
      University of California, San Francisco
    May 9, 2023

    Clear Cell Papillary Renal Tumor, Collecting Duct Carcinoma, Hereditary Leiomyomatosis and Renal Cell Carcinoma Trial in Los

    Recruiting
    • Clear Cell Papillary Renal Neoplasm
    • +10 more
    • Los Angeles, California
      UCLA / Jonsson Comprehensive Cancer Center
    Oct 25, 2021

    Glioma Trial in Tokyo (DS-1001b)

    Active, not recruiting
    • Glioma
    • Tokyo, Japan
      National Cancer Center Hospital
    Feb 2, 2022

    Advanced Malignancies That Harbor IDHR132 Mutations Trial in Worldwide (IDH305)

    Active, not recruiting
    • Advanced Malignancies That Harbor IDHR132 Mutations
    • Boston, Massachusetts
    • +12 more
    Dec 9, 2021

    Recurrent Acute Myeloid Leukemia Trial in United States (Enasidenib Mesylate, Liposome-encapsulated Daunorubicin-Cytarabine)

    Suspended
    • Recurrent Acute Myeloid Leukemia
    • Enasidenib Mesylate
    • Liposome-encapsulated Daunorubicin-Cytarabine
    • Los Angeles, California
    • +3 more
    Sep 27, 2022

    Glioma Trial (AB-218)

    Not yet recruiting
    • Glioma
    • (no location specified)
    Mar 29, 2022